journal article·2024-01Open access

Critical Design Strategies Supporting Optimized Drug Release from Polymer–Drug Conjugates

Snežana Đorđević, María Medel, Justine Hillaert, Esther Masiá, Inmaculada Conejos‐Sánchez, María J. Vicent

Small· Volume 20· Issue 4

Abstract

The importance of an adequate linking moiety design that allows controlled drug(s) release at the desired site of action is extensively studied for polymer‐drug conjugates (PDCs). Redox‐responsive self‐immolative linkers bearing disulfide moieties (SS‐SIL) represent a powerful strategy for intracellular drug delivery; however, the influence of drug structural features and linker‐associated spacers on release kinetics remains relatively unexplored. The influence of drug/spacer chemical structure and the chemical group available for conjugation on drug release and the biological effect of resultant PDCs is evaluated. A “design of experiments” tool is implemented to develop a liquid chromatography‐mass spectrometry method to perform the comprehensive characterization required for this systematic study. The obtained fit‐for‐purpose analytical protocol enables the quantification of low drug concentrations in drug release studies and the elucidation of metabolite presence. and provides the first data that clarifies how drug structural features influence the drug release from SS‐SIL and demonstrates the non‐universal nature of the SS‐SIL. The importance of rigorous linker characterization in understanding structure‐function correlations between linkers, drug chemical functionalities, and in vitro release kinetics from a rationally‐designed polymer‐drug nanoconjugate, a critical strategic crafting methodology that should remain under consideration when using a reductive environment as an endogenous drug release trigger.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Computational Drug Discovery Methods · Advanced Polymer Synthesis and Characterization

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Polymer Therapeutics Laboratory Príncipe Felipe Research Center (CIPF) and CIBERONC Eduardo Primo Yúfera 3 Valencia 46012 Spain

Screening Platform Príncipe Felipe Research Center (CIPF) Eduardo Primo Yúfera 3 Valencia 46012 Spain

Funding

Generalitat Valenciana · Fundación Científica Asociación Española Contra el Cáncer · Ministerio de Economía y Competitividad

References (62)

Show source-provided references
1. 10.1007/s13346-020-00740-510.1007/s13346-020-00740-5 ↗
2. 10.1038/s41568-022-00496-910.1038/s41568-022-00496-9 ↗
3. 10.1016/j.addr.2016.04.02510.1016/j.addr.2016.04.025 ↗
4. 10.1002/adhm.20200197410.1002/adhm.202001974 ↗
5. 10.1016/B978-0-323-52727-9.00003-010.1016/B978-0-323-52727-9.00003-0 ↗
6. 10.1016/j.addr.2007.11.00910.1016/j.addr.2007.11.009 ↗
7. 10.1016/j.addr.2020.06.00510.1016/j.addr.2020.06.005 ↗
8. 10.1021/acsnano.8b0610410.1021/acsnano.8b06104 ↗
9. 10.1016/j.addr.2020.10.00710.1016/j.addr.2020.10.007 ↗
10. 10.1039/D0RA04155F10.1039/D0RA04155F ↗
11. 10.1158/0008-5472.CAN-13-111710.1158/0008-5472.CAN-13-1117 ↗
12. 10.1016/j.jconrel.2014.06.01210.1016/j.jconrel.2014.06.012 ↗
13. 10.1039/C0PY00324G10.1039/C0PY00324G ↗
14. 10.1021/jo702051f10.1021/jo702051f ↗
15. 10.1021/acs.accounts.5b0040610.1021/acs.accounts.5b00406 ↗
16. 10.1021/acsmedchemlett.6b0023310.1021/acsmedchemlett.6b00233 ↗
17. 10.1186/s12951-018-0398-210.1186/s12951-018-0398-2 ↗
18. 10.1039/C6QM00135A10.1039/C6QM00135A ↗
19. 10.1016/j.jconrel.2018.04.01910.1016/j.jconrel.2018.04.019 ↗
20. 10.1016/j.bioorg.2013.06.00710.1016/j.bioorg.2013.06.007 ↗
21. 10.1016/j.aca.2009.06.01510.1016/j.aca.2009.06.015 ↗
22. Miller J. N. · Chemometrics for Analytical Chemistry · 2005 · 112
23. Kromidas S. · 2019 · 85
24. 10.1016/S0168-3659(01)00248-610.1016/S0168-3659(01)00248-6 ↗
25. 10.1002/marc.20190053110.1002/marc.201900531 ↗
26. 10.1002/cmdc.20190024810.1002/cmdc.201900248 ↗
27. 10.1039/C4RA12856G10.1039/C4RA12856G ↗
28. 10.1002/anie.20171165110.1002/anie.201711651 ↗
29. 10.1039/C5CC00405E10.1039/C5CC00405E ↗
30. 10.1021/acs.chemrev.5b0034610.1021/acs.chemrev.5b00346 ↗
31. 10.3390/polym602051510.3390/polym6020515 ↗
32. 10.1016/j.drudis.2015.09.01510.1016/j.drudis.2015.09.015 ↗
33. 10.1002/mabi.20160031610.1002/mabi.201600316 ↗
34. 10.1186/s12885-015-1948-810.1186/s12885-015-1948-8 ↗
35. 10.3390/cancers1401019010.3390/cancers14010190 ↗
36. 10.1021/jacs.8b0509310.1021/jacs.8b05093 ↗
37. 10.1039/c1ob06424j10.1039/c1ob06424j ↗
38. 10.1039/C8CC08533A10.1039/C8CC08533A ↗
39. 10.1002/anie.20046165710.1002/anie.200461657 ↗
40. 10.1039/C7OB00121E10.1039/C7OB00121E ↗
41. 10.1002/marc.20190053110.1002/marc.201900531 ↗
42. 10.1038/nmat377610.1038/nmat3776 ↗
43. Schafer F. Q. · Biol. Med. · 2001 · 30 · 1191
44. Vollhardt P. · 2018 · 276
45. 10.1124/dmd.118.08613210.1124/dmd.118.086132 ↗
46. 10.1002/adhm.20150034410.1002/adhm.201500344 ↗
47. 10.1017/S143192760808003310.1017/S1431927608080033 ↗
48. 10.1017/S003358350000429710.1017/S0033583500004297 ↗
49. 10.1002/adma.20170288810.1002/adma.201702888 ↗
50. 10.1002/smll.20140363210.1002/smll.201403632 ↗
51. 10.1021/acs.molpharmaceut.5b0094610.1021/acs.molpharmaceut.5b00946 ↗
52. 10.2217/17435889.2.3.26510.2217/17435889.2.3.265 ↗
53. 10.1002/bit.2191010.1002/bit.21910 ↗
54. 10.1039/C9BM01132C10.1039/C9BM01132C ↗
55. 10.1039/C7PY00559H10.1039/C7PY00559H ↗
56. 10.1002/mas.2155110.1002/mas.21551 ↗
57. 10.1002/mas.2012810.1002/mas.20128 ↗
58. 10.1007/s00216-018-1036-410.1007/s00216-018-1036-4 ↗
59. 10.1007/s13361-016-1344-x10.1007/s13361-016-1344-x ↗
60. 10.1016/j.biomaterials.2021.12105210.1016/j.biomaterials.2021.121052 ↗
61. 10.1002/adma.20080245310.1002/adma.200802453 ↗
62. 10.1016/S0040-4020(99)00809-110.1016/S0040-4020(99)00809-1 ↗